FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322774830> ?p ?o ?g. }

• W4322774830 endingPage "45" @default.
• W4322774830 startingPage "P4" @default.
• W4322774830 abstract "Abstract Background: Triple negative breast cancer (TNBC) is well known for its more aggressive course and poorer prognosis compared to other BC subtypes. RegistEM study provides real world data to understand the distribution of BC subtypes in the advanced setting, being its primary objective. Biological samples collection is part of its procedures. This is a non-interventional cohort study and 1,907 patients (pts) have been enrolled up to now (females and males) with advanced BC (ABC), diagnosed from Jan-2016 to Dec-2019, either after recurrence or as first BC diagnosis, in 38 Spanish sites. These pts will be followed for at least 5 years. Methods: In the current analysis (cut-off date 08/April/2022, database ongoing), we describe characteristics, treatment patterns and outcomes, including comparison between recurrent and de novo disease, of 157 pts with advanced TNBC included in the RegistEM study. Those pts represent the 10% of pts available in the database at the cut-off date and with ABC diagnosis up to December 2018 (n=1559). The BC clinical subtypes were histologically confirmed on the most recent tumor lesion (metastatic [M] or primary BC) before starting with the 1st-line therapy. Results: At first ABC diagnosis, 73% pts had recurrent early BC (EBC), 26% de novo MBC and 1% unresectable locally ABC (ULABC). Median age was 57 years (range 30-88), all pts were women, 98% Caucasian and 65% postmenopausal. Family history of BC and/or ovarian cancer was reported in 37% pts, and a hereditary-risk genetic test was performed in 59 of 147 pts. Germline BRCA1/2 and TP53 were the most frequently mutated genes, 21% (6/28) and 47% (8/17) pts, respectively. Visceral involvement was present in 69% pts (similar between recurrent EBC and de novo ABC, although brain metastases were only present in the recurrent EBC group), and ≤ 2 metastatic locations in 59%. In 61% (70/115) pts with recurrent EBC, the subtype was assessed in metastatic lesions, and 39 pts of them also had TN subtype in primary BC. In terms of the most frequent therapies by line: 1) 1st-line: chemotherapy (CT) (60%) and CT/biological therapy (BT) (39%). Of the 87 pts with CT alone, monotherapy was the preferred option in 57% pts (capecitabine 25%, taxanes 16%, and eribulin or vinorelbine, 5% each). Bevacizumab was the most frequent BT (79%) combined with CT (single agent in 56% pts, mostly taxanes and capecitabine). Progressive disease (PD) was reported in 85% pts (similar in pts with both recurrent and de novo MBC or ULABC); 2) 2nd-line: CT (79%) (monotherapy capecitabine, eribulin, taxanes) and CT/BT (17%) (CT-containing bevacizumab 82%). Progression was reported in 92% pts; 3) 3rd-line: CT (90%) (eribulin 33%, platinum-based 25%) and CT/BT (9%) (CT-containing bevacizumab 67%). Progression was reported in 88% pts. At database cut-off date, death was reported in 133 (85%) pts, mainly because of PD. Overall survival (OS) was similar between both groups, recurrent and de novo MBC. Conclusion: In this population of Spanish TNBC pts with ABC, three quarters had recurrent disease. De novo ABC pts had a higher proportion of non-visceral metastases, with absence of brain involvement at the first diagnosis. Single-agent CT and CT plus bevacizumab were the most frequent therapies, and OS was similar between recurrent and de novo MBC pts, although numerically higher in the later group. Citation Format: Silvia Antolin Novoa, César A Rodríguez, Josefina Cruz, Sara López-Tarruella, Ariadna Tibau, Encarna Adrover, Ana Miguel, Mireia Margelí, Purificación Martínez, María Hernández, Antonio Antón, Álvaro Rodríguez-Lescure, Catalina Falo, Isabel Álvarez, Diego Malón, Raquel Andrés, José L Alonso-Romero, César Gómez, J. José Illaramendi, Ruth Campo, Juan José Miralles, Susana Bezares, Federico Rojo, Angel Guerrero-Zotano. Treatment strategies for advanced triple negative breast cancer patients as per routine clinical practice: analysis from the observational study GEICAM/2014-03 (RegistEM) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-07-45." @default.
• W4322774830 created "2023-03-03" @default.
• W4322774830 creator A5011295593 @default.
• W4322774830 creator A5012974257 @default.
• W4322774830 creator A5015894044 @default.
• W4322774830 creator A5020462811 @default.
• W4322774830 creator A5030970489 @default.
• W4322774830 creator A5033648975 @default.
• W4322774830 creator A5034289968 @default.
• W4322774830 creator A5034517608 @default.
• W4322774830 creator A5035102028 @default.
• W4322774830 creator A5042388954 @default.
• W4322774830 creator A5043393829 @default.
• W4322774830 creator A5044744499 @default.
• W4322774830 creator A5048186707 @default.
• W4322774830 creator A5053404888 @default.
• W4322774830 creator A5056530621 @default.
• W4322774830 creator A5059890986 @default.
• W4322774830 creator A5065932039 @default.
• W4322774830 creator A5071202334 @default.
• W4322774830 creator A5074111929 @default.
• W4322774830 creator A5075755020 @default.
• W4322774830 creator A5077005205 @default.
• W4322774830 creator A5077254699 @default.
• W4322774830 creator A5083011111 @default.
• W4322774830 creator A5090790623 @default.
• W4322774830 date "2023-03-01" @default.
• W4322774830 modified "2023-09-23" @default.
• W4322774830 title "Abstract P4-07-45: Treatment strategies for advanced triple negative breast cancer patients as per routine clinical practice: analysis from the observational study GEICAM/2014-03 (RegistEM)" @default.
• W4322774830 doi "https://doi.org/10.1158/1538-7445.sabcs22-p4-07-45" @default.
• W4322774830 hasPublicationYear "2023" @default.
• W4322774830 type Work @default.
• W4322774830 citedByCount "0" @default.
• W4322774830 crossrefType "journal-article" @default.
• W4322774830 hasAuthorship W4322774830A5011295593 @default.
• W4322774830 hasAuthorship W4322774830A5012974257 @default.
• W4322774830 hasAuthorship W4322774830A5015894044 @default.
• W4322774830 hasAuthorship W4322774830A5020462811 @default.
• W4322774830 hasAuthorship W4322774830A5030970489 @default.
• W4322774830 hasAuthorship W4322774830A5033648975 @default.
• W4322774830 hasAuthorship W4322774830A5034289968 @default.
• W4322774830 hasAuthorship W4322774830A5034517608 @default.
• W4322774830 hasAuthorship W4322774830A5035102028 @default.
• W4322774830 hasAuthorship W4322774830A5042388954 @default.
• W4322774830 hasAuthorship W4322774830A5043393829 @default.
• W4322774830 hasAuthorship W4322774830A5044744499 @default.
• W4322774830 hasAuthorship W4322774830A5048186707 @default.
• W4322774830 hasAuthorship W4322774830A5053404888 @default.
• W4322774830 hasAuthorship W4322774830A5056530621 @default.
• W4322774830 hasAuthorship W4322774830A5059890986 @default.
• W4322774830 hasAuthorship W4322774830A5065932039 @default.
• W4322774830 hasAuthorship W4322774830A5071202334 @default.
• W4322774830 hasAuthorship W4322774830A5074111929 @default.
• W4322774830 hasAuthorship W4322774830A5075755020 @default.
• W4322774830 hasAuthorship W4322774830A5077005205 @default.
• W4322774830 hasAuthorship W4322774830A5077254699 @default.
• W4322774830 hasAuthorship W4322774830A5083011111 @default.
• W4322774830 hasAuthorship W4322774830A5090790623 @default.
• W4322774830 hasConcept C121608353 @default.
• W4322774830 hasConcept C126322002 @default.
• W4322774830 hasConcept C143998085 @default.
• W4322774830 hasConcept C187212893 @default.
• W4322774830 hasConcept C2775930923 @default.
• W4322774830 hasConcept C2780110267 @default.
• W4322774830 hasConcept C2781179581 @default.
• W4322774830 hasConcept C530470458 @default.
• W4322774830 hasConcept C71924100 @default.
• W4322774830 hasConcept C72563966 @default.
• W4322774830 hasConceptScore W4322774830C121608353 @default.
• W4322774830 hasConceptScore W4322774830C126322002 @default.
• W4322774830 hasConceptScore W4322774830C143998085 @default.
• W4322774830 hasConceptScore W4322774830C187212893 @default.
• W4322774830 hasConceptScore W4322774830C2775930923 @default.
• W4322774830 hasConceptScore W4322774830C2780110267 @default.
• W4322774830 hasConceptScore W4322774830C2781179581 @default.
• W4322774830 hasConceptScore W4322774830C530470458 @default.
• W4322774830 hasConceptScore W4322774830C71924100 @default.
• W4322774830 hasConceptScore W4322774830C72563966 @default.
• W4322774830 hasIssue "5_Supplement" @default.
• W4322774830 hasLocation W43227748301 @default.
• W4322774830 hasOpenAccess W4322774830 @default.
• W4322774830 hasPrimaryLocation W43227748301 @default.
• W4322774830 hasRelatedWork W144521535 @default.
• W4322774830 hasRelatedWork W1966181922 @default.
• W4322774830 hasRelatedWork W1999292713 @default.
• W4322774830 hasRelatedWork W2317787856 @default.
• W4322774830 hasRelatedWork W2366029130 @default.
• W4322774830 hasRelatedWork W2411890706 @default.
• W4322774830 hasRelatedWork W2554176272 @default.
• W4322774830 hasRelatedWork W2705094675 @default.
• W4322774830 hasRelatedWork W3044626609 @default.
• W4322774830 hasRelatedWork W80971072 @default.
• W4322774830 hasVolume "83" @default.
• W4322774830 isParatext "false" @default.
• W4322774830 isRetracted "false" @default.
• W4322774830 workType "article" @default.